Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2008

View Archived Issues

Novel cPLA2 alpha inhibitor presented at the ACS meeting

GSK-189254 shows in vivo efficacy against neuropathic, but not inflammatory, pain

AS-006 effective in vivo against inflammatory pain

AMRI initiates phase I study of tubulin inhibitor ALB-109564(a) in advanced solid tumors

Watson successfully completes pilot clinical study of Stellar's Uracyst in interstitial cystitis

FDA and Medco sign partnership to study pharmacogenetic testing of prescription drugs

Omeros and Affitech enter agreement for fully human antibodies for MASP-2

Leo Pharmaceuticals receives European approval for Xamiol for scalp psoriasis

Repros presents an update on phase II endometriosis study of Proellex

Regeneron and Bayer HealthCare announce results from a phase II study of VEGF Trap-Eye

Allergan divulges new therapeutic agents for glaucoma in a recent patent

Recent Panacea Biotec patent discloses novel antibacterial agents

Schering-Plough launches asthma inhaler Asmanex Twisthaler in the U.S.

New agents for treating neurological disorders described in recent patent literature

Transplantation of islet cells with Sertoli cells may be feasible for diabetes treatment

Further PROMISE data show efficacy of voclosporin in renal transplantation

Pfizer's PDE10A inhibitor PF-254920 may be useful for the treatment of schizophrenia

Vical's Vaxfectin adjuvant to be tested with preventive DNA vaccine against HIV

Bristol-Myers Squibb and PDL enter global alliance in multiple myeloma

Cel-Sci enters exclusive licensing agreement with Teva for cancer drug Multikine

Neurologix starts recruitment in phase II gene transfer trial in Parkinson's disease

Viralytics doses second patient group in Cavatak phase I melanoma trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...